TABLE 2

Frequencies of latent tuberculosis infection (LTBI) treatment completion and severe hepatic events, and mean direct health system costs during LTBI treatment^#, stratified by patient age group and co-morbidity^¶,+,§

	With co-morbidity by age years				No co-morbidity by age years				All patients
	0–19	20–34	35–64	≥65	0–19	20–34	35–64	≥65
Number of people n
R	8	20	87	106	55	289	280	30	875
H	132	228	356	183	2164	2777	3434	410	9684
Treatment completion %
R	28.6	30.0	18.7	16.4	61.6	66.8	63.5	39.4	53.5
H	19.4	22.1	28.2	27.7	33.8	25.3	28.3	34.0	36.9
Severe adverse events hepatic n (%) ^ƒ
R	0	0	0	1 (0.9)	0	0	0	0	1 (0.1)
H	0	1 (0.4)	2 (0.6)	2 (1.1)	2 (0.09)	2 (0.07)	5 (0.2)	1 (0.2)	15 (0.2)
TB drug costs mean CAD
R	212	170	225	265	252	257	267	281	256
H	152	74	80	68	182	75	80	77	102
Other costs mean CAD
R	12 089	4571	9651	8587	341	223	591	8558	2793
H	2540	5813	13 090	25 280	556	660	2227	8491	2593

^#: patients starting LTBI treatment with H or R in Quebec between 2003 and 2007 (N=10 559). ^¶: Co-morbidity defined as having one or more hospitalisations in the year before LTBI treatment start. ⁺: Treatment completion for 9H was 270 doses dispensed in 12 months and for 4R was 120 doses dispensed in 6 months. ^§: Costs during LTBI treatment period (from first date with a TB drug dispensed to 30 days after the last TB drug dispensed, limited to a period of up to 12 months for H and 6 months for R). Costs reported in 2011 Canadian dollars (CAD; rounded to the nearest dollar). “Other costs” include all Régie de l'assurance maladie du Québec-paid costs, except those for TB drugs (i.e. sum of hospitalisations, emergency department visits, hospital day procedures, physician billing, and non-TB drugs dispensed). ^ƒ: Included liver transplants (n=2) and hospitalisations ending in death (n=1), all occurring in H patients.